Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV

Parkside Financial Bank & Trust trimmed its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 46.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 698,520 shares of the company’s stock after selling 611,021 shares during the period. Roivant Sciences comprises approximately 0.8% of Parkside Financial Bank & Trust’s investment portfolio, making the stock its 21st biggest position. Parkside Financial Bank & Trust owned approximately 0.10% of Roivant Sciences worth $10,569,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ROIV. CWM LLC increased its stake in shares of Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the period. Osaic Holdings Inc. increased its position in Roivant Sciences by 204.2% during the 2nd quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after purchasing an additional 3,882 shares during the period. UMB Bank n.a. raised its holdings in Roivant Sciences by 42.0% during the 2nd quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock worth $66,000 after purchasing an additional 1,740 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Roivant Sciences by 22.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,978 shares of the company’s stock worth $90,000 after purchasing an additional 1,485 shares during the period. Finally, Rossby Financial LCC acquired a new position in shares of Roivant Sciences in the 2nd quarter worth approximately $113,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 1,018,995 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the completion of the sale, the insider directly owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. The trade was a 4.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 353,745 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $22.05, for a total value of $7,800,077.25. Following the completion of the transaction, the insider owned 34,132,463 shares in the company, valued at $752,620,809.15. This represents a 1.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,332,392 shares of company stock valued at $266,393,645 over the last quarter. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $22.97 on Friday. The firm has a market capitalization of $15.98 billion, a price-to-earnings ratio of -41.02 and a beta of 1.22. The business has a 50-day simple moving average of $21.67 and a 200 day simple moving average of $16.93. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $23.91.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ROIV shares. Citigroup increased their price objective on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a report on Thursday, December 18th. The Goldman Sachs Group boosted their price objective on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. HC Wainwright raised their target price on Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.